GAO says FDA's allowance of pharmacies to dispense abortion pill was not subject to congressional review
The US Government Accountability Office concluded on Thursday that the FDA’s decision to allow certain pharmacies to dispense the abortion pill mifepristone is not subject to congressional review.
The FDA modified mifepristone’s risk evaluation and mitigation strategy (REMS) in January to permit certain certified pharmacies to offer Danco Laboratories’ brand-name Mifeprex pills and a generic manufactured by GenBioPro. Previously, patients were required to receive the drug in a clinic, medical office or hospital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.